NEUROCRINE BIOSCIENCES INC holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 5,534,624 | $612,129,414 | 0.35% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2025 |
| June 30, 2025 | 5,566,814 | $699,692,852 | 0.39% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2025 |
| Sept. 30, 2025 | 5,556,618 | $780,038,035 | 0.42% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 13, 2025 |
| Dec. 31, 2025 | 5,508,042 | $781,205,597 | 0.42% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 13, 2026 |
| March 31, 2026 | 5,461,037 | $719,437,014 | 0.40% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 14, 2026 |
| June 30, 2026 | 5,584,707 | $941,218,594 | 0.49% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 13, 2026 |
6 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
NEUROCRINE BIOSCIENCES INC · SC 13G · Event March 31, 2025 · Filed May 14, 2025
| Reporting person | Reported shares | % of security class | Group box |
|---|---|---|---|
| Dodge & Cox | 5,534,624 | 5.6% | Unavailable |
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.